GlobeNewswire

Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq

Share


  • Company anticipates the first day of trading on U.S. Nasdaq will be during the fourth
    quarter, 2021
  • A previously-announcedU.S. $20 million investment by 3iFund supports Company’s transition to the U.S. Nasdaq

Press release

Hørsholm, Denmark
(August 23,2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that its wholly-owned subsidiary, Allarity Therapeutics, Inc., a Delaware corporation, (hereinafter “Allarity US Inc.”). has filed a Form S-4 Registration Statement (“Form S-4”) with the U.S. SEC relating to its proposed Recapitalization Share Exchange and in anticipation of filing an application for a listing of Allarity US Inc.’s shares on the U.S. Nasdaq. The filing of the Form S-4 follows the Company’s prior announcement, on May 21, 2021, that it had entered into a definitive Securities Purchase Agreement with 3i Fund (New York, NY U.S.A.) (“3i”) for a U.S. $20 million investment (“Securities Purchase Agreement”) to support the Company’s recapitalization, reorganization, and migration to the U.S. Nasdaq Stock Market.

As previously announced, 3i will invest U.S. $20 million directly into Allarity US Inc., which has been organized as a wholly owned subsidiary of the Company and will become a U.S. based holding company of the Company’s business operations after the Recapitalization Share Exchange is completed. As part of the recapitalization transaction, Allarity US Inc. will, through a special purpose wholly owned subsidiary, purchase substantially all of the assets and assume substantially all of the liabilities of the Company in exchange for shares of common stock of Allarity US Inc., and an application will be made to have the shares listed for trading on the U.S. Nasdaq Stock Market conditioned upon completion of the recapitalization.

Allarity’s CEO Steve Carchedi noted, “This is anotherimportanttransformative milestone in our Company’s history, which we believe will enable us to unlock shareholder value and achieve market values in line with our U.S. Nasdaq-listed peer group. We also remain grateful to have the continuing support of 3i Fund to help us in this major transition. We look forward to listing on the U.S. Nasdaq and to upholding our mission of realizing the promise of personalized medicine for cancer patients through advancing our pipeline programs and DRP® companion diagnostics.”

Further details about the recapitalization and reorganization plan, and migration to the U.S. stock market, are detailed in the Form S-4 filing (SEC File No. 333-258968) which can be found on the SEC website: https://www.sec.gov/edgar/searchedgar/companysearch.html)

The 3i Fund investment is conditioned upon i) shareholder approval, ii) the completion of the recapitalization, iii) acceptance of the listing application for the Allarity US Inc. common stock by the U.S. Nasdaq Stock Market, and iv) an effective registration statement filed with the SEC.

Following the Form S-4 filing with the SEC, Allarity Therapeutics anticipates that the target date for completion of the Recapitalization Share Exchange and anticipated listing on the U.S. Nasdaq stock market will be during the fourth quarter of 2021, subject to necessary approvals.

An extraordinary general meeting of the Company’s shareholders will be convened once the registration statement filed with the SEC has been declared effective and at that time all shareholders will receive an information statement and prospectus that will describe the Recapitalization Share Exchange transaction and 3iFund investment in greater detail before voting on the transaction at the extraordinary meeting.

Upon the completion of the Recapitalization Share Exchange transaction, the Company anticipates that the Company’s ordinary shares will no longer be listed for trading on the First North Growth Market (Stockholm, SE) and the shares of Allarity US Inc. common stock will be distributed to the Company’s shareholders by an anticipated share buy-back (exchange) program, or an extraordinary or liquidating dividend.  

Upon the completion of the Recapitalization Share Exchange, the Company’s new global headquarters will be on the East Coast of the U.S., where Allarity US Inc. and a majority of its executive team is currently based. Allarity US Inc. will maintain its existing facilities in Denmark as a research and development (R&D) center, including a clinical diagnostics laboratory that can run DRP® companion diagnostic analysis for EU-based clinical trials and/or for marketed drugs.

About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. By screening patients before treatment, the response rate can be significantly increased. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. DRP® is based on messenger RNA from the patient’s biopsies. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in nearly 40 clinical studies that were examined, including an ongoing, prospective Phase 2 trial. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs.

About AllarityTherapeutics
Allarity Therapeutics (Nasdaq First North Growth Market Stockholm: ALLR.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, the DRP® platform. The company has a mature portfolio of six drug candidates, including compounds in the pre-registration stage. The product portfolio includes: Stenoparib (2X-121), a PARP inhibitor in Phase 2 for ovarian cancer; Dovitinib, a pan-TKI advancing towards a U.S. NDA filing for renal cell carcinoma; IXEMPRA® (Ixabepilone), a microtubulin inhibitor approved in the U.S. for the treatment of breast cancer; LiPlaCis®, a liposomal formulation of cisplatin in Phase 2 trials for breast and prostate cancer, currently being developed by Smerud Medical Research International; 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer, currently being developed by Smerud Medical Research International; and Irofulven, a DNA damaging agent in Phase 2 for prostate cancer, currently being developed by Lantern Pharma, Inc.

Follow us on social media:
Facebook: https://www.facebook.com/AllarityTx/
LinkedIn: https://www.linkedin.com/company/allaritytx/
Twitter: https://twitter.com/allaritytx

About 3iFund

3i Fund is dedicated to working with companies on an individual level to understand their vision and growth objectives. The firm provides investment capital to help support the progress of our innovative and high-potential partners.
Contact: azinberg@3ifund.com

Important Information About the Recapitalization Share Exchange and Where to Find It.

This press release relates to a proposed Recapitalization transaction between Allarity Therapeutics, Inc., a Delaware corporation and a wholly owned subsidiary of Allarity Therapeutics A/S. A full description of the terms and conditions of the Plan of Reorganization and Asset Purchase Agreement constituting the recapitalization is provided in the registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission (SEC) by Allarity Therapeutics, Inc., that includes a prospectus with respect to the securities to be issued in connection with the recapitalization, and information with respect to an extraordinary meeting of Allarity Therapeutics A/S shareholders to vote on the recapitalization and related transactions. Allarity Therapeutics, Inc. and Allarity Therapeutics A/S urges its investors, shareholders and other interested persons to read the information statement and prospectus as well as other documents filed with the SEC because these documents will contain important information about Allarity Therapeutics, Inc., Allarity Therapeutics A/S, and the recapitalization transaction. After the registration statement is declared effective, the definitive information statement and prospectus to be included in the registration statement will be distributed to shareholders of Allarity Therapeutics A/S, as of a record date to be established for voting on the proposed recapitalization and related transactions. Shareholders may obtain a copy of the Form S-4 registration statement, including the information statement and prospectus, and other documents filed with the SEC without charge, by directing a request to: Allarity Therapeutics A/S at Venlighedsej 1, 2970 Horsholm, Denmark. The preliminary and definitive information statement and prospectus included in the registration statement can also be obtained, without charge, at the SEC’s website (www.sec.gov).

Participation in the Solicitation

Allarity Therapeutics, Inc., Allarity Therapeutics A/S, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies or consents from Allarity Therapeutics A/S shareholders in connection with the proposed transaction. A list of the names of the directors and executive officers of Allarity Therapeutics, Inc. and Allarity Therapeutics A/S and information regarding their interests in the recapitalization transaction is contained in the information statement and prospectus . You may obtain free copies of these documents as described in the preceding paragraph.

Forward-Looking Statements

This document contains certain forward-looking statements within the meaning of the federal securities laws with respect to the proposed transaction between Allarity Therapeutics, Inc. (“Allarity US”) and Allarity Therapeutics A/S (“Allarity A/S”). These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect the price of Allarity A/S’s securities, (ii) the failure to satisfy the conditions to the consummation of the transaction as contemplated in the Plan of Reorganization and Asset Acquisition Agreement (the “Recapitalization Agreement”), by the shareholders of Allarity A/S, the satisfaction of the conditions to the Recapitalization Agreement, including the listing of Allarity US common stock on the Nasdaq Stock Market and the receipt of certain governmental and regulatory approvals, (iii) the inability to complete the 3i Fund investment in connection with the transaction, (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Recapitalization Agreement, (v) the effect of the announcement or pendency of the transaction on Allarity A/S business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations of Allarity A/S and potential difficulties in Allarity A/S employee retention as a result of the transaction, (vii) the outcome of any legal proceedings that may be instituted against Allarity A/S or against Allarity US related to the Recapitalization Agreement or the transaction, (viii) the ability to obtain the listing of Allarity US’s securities on a national securities exchange, (ix) the price of Allarity US’s securities may be volatile due to a variety of factors, including changes in the competitive and highly regulated industries in which Allarity US plans to operate or Allarity A/S operates, variations in operating performance across competitors, changes in laws and regulations affecting Allarity US’s or Allarity A/S’s business and changes in the combined capital structure, (x) the ability to implement business plans, forecasts, and other expectations after the completion of the transaction, and identify and realize additional opportunities, and (xi) the risk of downturns and a changing regulatory landscape in Allarity US’s highly competitive industry. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Allarity US’s registration statement on Form S-4 discussed above and other documents filed by Allarity US from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law Allarity US and Allarity A/S assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Allarity US nor Allarity A/S gives any assurance that either Allarity US or Allarity A/S or the recapitalized company will achieve its expectations.

Any financial projections in this communication are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond Allarity US’s and Allarity A/S’s control. While all projections are necessarily speculative, Allarity US and Allarity A/S believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection extends from the date of preparation. The assumptions and estimates underlying the projected results are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the projections. The inclusion of projections in this communication should not be regarded as an indication that Allarity US and Allarity A/S, or their representatives, considered or consider the projections to be a reliable prediction of future events.

###

Investor Contacts:

        InvestorRelations@allarity.com

U.S. Media Contact

        Mike Beyer
        Sam Brown, Inc.
        +1 312-961-2502
mikebeyer@sambrown.com

EU Media Contact

        Thomas Pedersen
        Carrotize PR & Communications
        +45 6062 9390
tsp@carrotize.com

Placement Agent
LifeSci Capital LLC acted as the exclusive placement agent on behalf of Allarity Therapeutics A/S.

U.S. Legal Counsel
Scott Bartel, Esq., Lewis Brisbois Bisgaard & Smith LLP, 633 West 5th Street, Suite 4000, Los Angeles, CA 90071. +1 (213) 250-1800

Certified Adviser
Svensk Kapitalmarknadsgranskning AB, Email: ca@skmg.se. Tel: +46 11 32 30 732

This information is information that Allarity A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on August 23, 2021.


Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)17.9.2021 13:30:00 CEST | Press release

PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues At 24 weeks, 38% of patients achieved ≥20% reduction in the volume of the PROS lesions assessed in the primary endpoint analysis; no patients experienced disease progression or death Alpelisib is the first potential treatment to specifically address the root cause of PROS conditions EPIK-P1 study findings presented at ESMO Virtual Congress 2021 support FDA submission Basel, September 17, 2021— Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and improved signs and symptoms in pediatric and adult patients. Resu

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS17.9.2021 13:15:00 CEST | Press release

Mechelen, Belgium;17September 2021;13.15 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced todaythatthe European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issueda positive opinion for Jyseleca® (filgotinib), a once-daily, oral, JAK1preferential inhibitor for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. Following this positive opinion, a final decision from the European Commission is expected later this year. The CHMP positive opinion is based on data from the pivotal Phase 2b/3 SELECTION program, which evaluated filgotinib as an induction and maintenance therapy in adult patients with moderately to severely active UC who have failed conventional therapy or biologics. SELECTION comprised two placebo-controlled induction studies, one in biologic-naive patients and the o

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer17.9.2021 13:10:00 CEST | Press release

Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. “This positive CHMP opinion for Gavreto represents another important step towards our goal of providing effective therapeutics that target genomic drivers of disease for as many cancer patients as possible," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Developmen

Elina Stråhlman appointed as Enento Group’s acting CEO17.9.2021 13:00:00 CEST | Press release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE ON 17 SEPTEMBER 2021 AT 2.00 P.M. EEST Elina Stråhlman appointedas Enento Group’s acting CEO As communicated with a stock exchange release on 21 April 2021, Enento Group Plc’s current CEO Jukka Ruuska has given notice of his resignation from the company no later than 31 October 2021. As announced in July, Jeanette Jäger will start as the new CEO and member of the Executive Management Team on 1 January 2022. Since 2016 she has worked in the Swedish company Bankgirot, first as VP Digital Services and from 2017 as CEO of Bankgirot. Enento Group's Board of Directors has today appointed Elina Stråhlman, the Group’s CFO, as an acting CEO for the interim period from 1 November 2021 to 31 December 2021. ENENTO GROUP PLC For further information: Jukka Ruuska CEO Tel. +358 10 270 7111 Distribution: Nasdaq Helsinki Major media enento.com/investors Enento Group is a Nordic knowledge company powering society with intelligence since 1905. We collect and trans

Fobi Launches Connected Retail Commerce Solution At Industry’s Premier Event For Convenience, Grocers and CPG Brands17.9.2021 12:00:00 CEST | Press release

Fobi CEO Rob Anson and Senior Vice President of Business Development Mike Canevaro to launch new Personalized Digital Receipt Marketing Solution at GroceryShop to be held September 19-22 in Las Vegas, Nevada VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Fobi AI Inc. (TSX.V: FOBI) (OTCQB: FOBIF) (the "Company" or "Fobi"), a global leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, is excited to announce the launch of its latest solution. The Fobi connected retail commerce solution will support real-time POS data connectivity across all banners and channels, in-store, online and mobile to provide retailers and CPG manufacturers with the ability to deliver automated and personalized marketing at scale. PERSONALIZED MARKETING TO EMPOWER CPG BRANDS BY PROVIDING THEM WITH DIRECT ACCESS TO ENGAGE CONSUMERS WITH PROMOTIONS AND CAMPAIGN ACTIVATION MEASUREMENT Fobi will now enable manufacturer brands to gain

RESULT OF RIKSBANK REVERSED AUCTIONS SEK GOVERNMENT BONDS17.9.2021 10:07:00 CEST | Press release

Auction date2021-09-17Loan1059Coupon1.00 %ISIN-codeSE0007125927Maturity2026-11-12Tendered volume, SEK mln500 +/- 250Volume offered, SEK mln1,000Volume bought, SEK mln500Number of bids2Number of accepted bids1Average yield-0.028Lowest accepted yield-0.028Highest yield-0.028% accepted at lowest yield 100.00 Auction date2021-09-17Loan1062Coupon0.125 %ISIN-codeSE0013935319Maturity2031-05-12Tendered volume, SEK mln750 +/- 350Volume offered, SEK mln1,750Volume bought, SEK mln750Number of bids5Number of accepted bids1Average yield0.277Lowest accepted yield0.277Highest yield0.277% accepted at lowest yield 100.00

Riksgälden föreslår i stort oförändrade riktlinjer för statsskulden17.9.2021 09:30:00 CEST | Pressemelding

Riksgälden föreslår i stort oförändrade riktlinjer för statsskulden Riksgälden föreslår inga väsentliga ändringar i riktlinjerna för förvaltningen av statsskulden.Förslaget till riktlinjer för 2022lämnas till Finansdepartementet i dag. Riksgälden ser inte behov av några större ändringar i riktlinjerna efter att de justeringar som gjorts de senaste åren har lett till en mer övergripande styrning av skuldförvaltningen. Därmed har Riksgälden god flexibilitet att hantera stora variationer i statens lånebehov inom de ramar som riktlinjerna ger. Regeringen beslutar om riktlinjerna varje år senast den 15 november. Beslutet fattas efter att Riksgälden har lämnat sitt förslag och Riksbanken har yttrat sig över förslaget. I riktlinjerna fastställs bland annat hur statsskulden ska vara sammansatt och vilken löptid den ska ha. Riktvärden för sammansättning och löptid ligger fast Sammansättning Real kronskuld – andelen ska långsiktigt vara 20 procent av statsskulden.Skuld i utländsk valuta – expone